Grupo LETI

What Grupo LETI does

Grupo LETI is a Venezuelan-headquartered pharmaceutical group with operational roots dating to 1945 and formal incorporation in 1950. The group operates three specialized business units: Leti, focused on branded generics and prescription pharmaceuticals; Genven, oriented to biotechnology-derived and biologics-adjacent products; and Biocontrolled, which covers natural-source and phytopharmaceutical health products. Its core offering is a portfolio of 420+ health registrations spanning OTC, prescription, and combination therapies across therapeutic categories including respiratory, anti-inflammatory, antifungal, cardiovascular, and dermatology.

The group manufactures across six production plants and 22 lines, totaling approximately 39,375 m² of installed manufacturing capacity and producing over 100 million pharmaceutical units annually. It holds GMP certification (renewed 2023) and ISO 9001:2015 certification, supporting both domestic Venezuelan distribution and export markets. Geographically, the group operates in Venezuela as its home base, expanded into Central America in 2009, and acquired Ecuadorian pharmaceutical manufacturer MEGAT in 2019, giving it Andean and Central American commercial reach. Recent product introductions — Surfactante B, Diklason BI, IZABAN, Maxoten, and Racor Dúo — indicate active portfolio renewal across respiratory, anti-inflammatory, antifungal, cardiovascular, and combination therapy categories.

The business model is a vertically integrated, B2B-and-B2C pharmaceutical manufacturer-distributor that monetizes primarily through unit sales of branded generics and OTC products via wholesale distributors, pharmacy chains, hospital procurement channels, and direct physician relationships. The group employs approximately 1,300 people. Strategic R&D and talent development are supported through a 2023 partnership with the Universidad Central de Venezuela (UCV). ESG and operational sustainability credentials are evidenced by a 2026 Ecolab R3 Award for water reuse. No meaningful public signals exist around AI/ML-driven drug discovery or AI-native operating models; the operational footprint appears to rely on standard process automation consistent with GMP-compliant manufacturing.

Name

Grupo LETI

Legal name

Laboratorios LETI S.A.V.

Website

https://grupoleti.com

Company type

Private

Founded year

1950

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Grupo LETI is a Venezuelan pharmaceutical group operating three units (Leti, Genven, Biocontrolled) that manufacture and distribute branded generics, biotechnology-derived, and natural-source health products across Venezuela, Ecuador, and Central America, serving pharmacy, hospital, and institutional channels.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Prescription pharmaceuticals
• Generic medications
• Modified release drugs
• Pharmaceutical nanotechnology
• Phytomedicines

Headquarters

HQ city

Guarenas

HQ country

Venezuela

HQ region

Latin America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Ethical/Prescription Pharmaceuticals (RX): Prescription pharmaceutical products (Éticos) for clinically significant conditions including cardiovascular, metabolic, gastric, respiratory, neurological, musculoskeletal, pain, antibiotics, and vitamins for pediatric and adult patients. Sold through pharmacy network and hospitals.
2. OTC / Over-The-Counter Products: Free-sale pharmaceutical products (OTC) acquirable without a medical prescription, placed on open shelving in pharmacy chains for direct consumer access.
3. Generic Medicines (Genven): Generic pharmaceutical line with more than 30 years in the Venezuelan market, offering first-line therapies in cardiovascular, anti-infectives, anti-inflammatory, and analgesic therapeutic areas. Includes accessible reduced-content presentations program reaching over 5 million units.
4. Phytomedicines / Fitofármacos: Medicines manufactured exclusively with standardized natural active ingredients from plants, developed through a complex manufacturing process yielding standardized extracts that guarantee therapeutic effect. Includes FitoLETI line.
5. Oncology / Hospital Products: Specialized hospital products including Surfactante B for neonatology and oncology-focused pharmaceutical solutions distributed through hospital channels.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

Grupo LETI manufactures and commercializes a broad pharmaceutical portfolio through three integrated business units: Leti (prescription ethical drugs, OTC, phytomedicines FitoLETI, oncology, and nanotechnology products), Genven (generic medications for cardiovascular, anti-infective, anti-inflammatory and analgesic therapies), and Biocontrolled (R&D and production of modified-release and nanotechnology drug delivery technologies). The portfolio spans 15+ pharmaceutical forms across cardiovascular, metabolic, gastrointestinal, respiratory, neurological, musculoskeletal, anti-infective, oncological, gynecological, and pediatric therapeutic areas, manufactured across 6 specialized plants and 22 production lines with 420 health registrations.

Product overview

Grupo LETI is Venezuela's largest pharmaceutical group with 75+ years of experience, operating three integrated business units: Leti (prescription ethical drugs, OTC, and phytomedicine), Genven (generic medications), and Biocontrolled (innovation unit for modified-release and nanotechnology pharmaceuticals). The portfolio spans cardiovascular, metabolic, gastrointestinal, respiratory, neurological, musculoskeletal, anti-infective, oncological, gynecological, and pediatric therapeutic areas. Biocontrolled develops advanced technologies including nanotechnology, modified-release, bicapa/biphasic systems, and gastric retention platforms. Products include branded medications (IZABAN, Maxoten, Diklason BI, Racor Dúo, Orofeno, CLENOSAN, Doxium, Surfactante B), generic medications under Genven, phytomedicines under FitoLETI, and gynecological line products (Caricel, Galby, Fomene, Genesa). Manufacturing capabilities include 22 production lines across 6 plants producing solids, liquids, injectables, penicillin, cephalosporin, and food products. Distribution channels include major pharmacy chains (Farmatodo, Locatel, Farmadon, Farmabien, Nuevo Siglo).

Differentiator

Problem solved

Functional benefit

Brands

• Leti: Core prescription (ethical), OTC, OTX, natural phytomedicines (FitoLETI), oncological, nanotechnology and genetic tests product lines.
• Genven
• Biocontrolled
• FitoLETI

Products and services

• IZABAN (Empagliflozina) Empagliflozina product offering three therapeutic actions in a single national formulation — for type 2 diabetes, heart failure, and nephroprotection in chronic kidney disease. Targeted at cardiometabolic specialists via the Cardio-Metabolic marketing unit.
• Maxoten (Eplerenona) Eplerenona for heart failure and post-myocardial infarction patients; aldosterone antagonist that lowers cardiovascular risk. Marketed to cardiologists and internists.
• Diklason BI (Diclofenac Potásico 150mg bicapa) First-in-country Diclofenac Potásico 150 mg with Biocontrolled bicapa controlled-release technology, delivering 24-hour pain and inflammation relief per dose. For physicians managing chronic pain/inflammation under medical supervision.
• Racor Dúo (Rosuvastatina + Ezetimiba) Rosuvastatin + Ezetimibe fixed-dose combination, the only nationally produced formulation in Venezuela, for patients requiring combined statin therapy at high doses.
• Orofeno (Ketoprofeno bicapa) Bilayer tablet of Ketoprofen 150 mg developed by Biocontrolled providing immediate and 12-hour sustained anti-inflammatory and analgesic action in a single dose.
• CLENOSAN (Ticagrelor) Ticagrelor antiplatelet therapy, the first nationally produced formulation of this active principle in Venezuela, for prevention of thrombotic events in adult patients with acute coronary syndrome.
• Doxium (Dobesilato de Calcio) Calcium dobesilate phlebotonic for treatment of Peripheral Venous Insufficiency, introduced to 80 cardiovascular specialists at the LIV Venezuelan Cardiology Congress 2023.
• Línea Ginecológica (Caricel, Galby, Fomene) Three branded gynecological hormone therapy products — Caricel, Galby, and Fomene — backed by bioequivalence studies for the Venezuelan women's health market.
• Genesa (Contraceptive line) Contraceptive line with Genesa 20 (launched 2023); Genesa is described as the most prescribed contraceptive by doctors in Venezuela, with over 706,000 treatment cycles provided across four years.
• Surfactante B (Bovine Pulmonary Surfactant) Bovine lung phospholipid pulmonary surfactant for neonatal Respiratory Distress Syndrome (RDS), the first nationally produced formulation with quality seal; targeted at hospital neonatology units and reduces neonatal RDS mortality to below 10%.
• Diglet 200 UI Gotas Pediátricas Pediatric Vitamin D3 (cholecalciferol) 200 IU oral drops, formulated as an innovative liquid preparation addressing the absence of pediatric Vitamin D3 drops in the Venezuelan market.
• BIoletisan Forte Phytopharmaceutic antioxidant combining standardized French Maritime Pine bark extract (50 mg) with Vitamin C (500 mg), backed by over 400 clinical studies, positioned in OTC self-service pharmacy sections.
• FiberFit Plus Natural fiber supplement (Glucomannan + Plantago ovata husk) for intestinal regulation and constipation relief, part of the FitoLETI phytomedicine line.
• Letisan (Vitamin C) Emblematic Grupo LETI Vitamin C product family with over 70 years in market, available in multiple presentations — solution, drops, capsules, and chewable tablets; recent extensions include Letisan 1,000 mg sugar-free tablets and grape-flavored chewable tablets.
• Alivet (Family products, including Alivet Plus) OTC product family for treating acute viral syndrome and the common cold, with Alivet Plus positioned via pharmacy-staff training (MED Comercial) reaching 170 professionals from 45 pharmacies.
• FENACTEL (Nanotechnology product) First nanotechnology-developed pharmaceutical product approved by Biocontrolled in 2020, applying Biocontrolled's nanoparticle-based drug delivery platform.
• Leti — Ethical Prescription (RX) Portfolio Main prescription drug line of Grupo LETI covering cardiovascular, metabolic, gastric, respiratory, neurological, musculoskeletal, pain, antibiotic, and vitamin therapeutic areas for pediatric and adult patients; promoted through 2,000+ specialist physicians via delegados de promoción.
• Leti OTC (Over The Counter) Portfolio Over-the-counter pharmaceuticals acquirable without medical prescription, placed on self-service pharmacy shelves of major Venezuelan chains (Farmatodo, Locatel, etc.) for direct consumer access.
• FitoLETI Phytomedicine Portfolio Medicines manufactured exclusively with standardized natural active ingredients from plants, developed through complex manufacturing processes; clinically validated with international licenses and published studies (includes BIoletisan Forte, FiberFit Plus, BIoletisan).
• Genven Generic Pharmaceutical Portfolio Generic pharmaceutical line with over 30 years in the Venezuelan market, covering first-line therapies in cardiometabolic, gastrointestinal, respiratory, hematologic, musculoskeletal, CNS, anti-infective, cardiovascular, anti-inflammatory, and analgesic therapeutic areas; includes the accessible reduced-content presentations program placing over 5 million units in 2023.
• Oncology / Hospital Specialty Products Specialized hospital pharmaceutical products distributed through hospital procurement channels, including Surfactante B for neonatology and oncology-focused injectable solutions for the onco-hospitalary unit.

Quantifiable outcome

• Venezuelan pharmaceutical market grew 17.49% in 2025, with national production contributing 74.24% of growth
• +9 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• Fundación Casa Venezolana del CorazónminorStrategic or Co-development Partner · 1 January 2025Alliance with the Venezuelan Heart Foundation and the Venezuelan Cardiology Society to conduct a media roundtable emphasizing the importance of cardiovascular disease prevention in women. Part of Grupo LETI's 75th anniversary activities and broader CSR program.
• Sociedad Venezolana de CardiologíacoreStrategic or Co-development Partner · 1 January 2025Strategic alliance with the Venezuelan Cardiology Society for medical congress sponsorship, continuing medical education, and cardiovascular health awareness initiatives. Grupo LETI has been a strategic partner for over 40 years, supporting the annual Cardiology Congress and related medical activities.
• Club del AsmaminorStrategic or Co-development Partner · 1 January 2025Collaboration with the Club del Asma (asthma physicians group) to address respiratory disease prevalence in San Pedro de Coche. Included medical outreach jornada, nebulization room rehabilitation, telemedicine installation, and respiratory medication donations through the Compromiso CSR program.
• Corporación DigitelminorGTM or Marketing Partner · 1 January 2025Digitel provided connectivity support through its Conexión Social program to install telemedicine equipment at the San Pedro de Coche ambulatory, enabling remote medical follow-up as part of Grupo LETI's Compromiso CSR program.
• Nalco Water (Ecolab)coreTechnology or Integration · 1 January 2024Nalco Water, a division of Ecolab, partnered with Grupo LETI over 24 months to implement the 3D automatic analyzer system that monitors water quality and doses chemical products, reducing manual intervention and waste. This partnership generated the results that earned Grupo LETI the R3 Award, including 16.5M liters water savings annually, 1 tonne salt reduction, and 55% reduction in chemical consumption.
• Universidad Central de Venezuela (UCV)coreStrategic or Co-development Partner · 1 January 2023Marco Agreement Nro.12-2023 signed between Grupo LETI and UCV for a 4-year initial period. Enables participation in medical and pharmaceutical congresses, job fairs, internship programs (extending beyond the School of Pharmacy to all faculties), knowledge exchange in areas of mutual interest, and scientific and technological cooperation. Ramón Estévez, Vice Executive President of Grupo LETI, signed on behalf of the company.
• Sociedad Venezolana de Gastroenterología (SOVEGASTRO)coreStrategic or Co-development Partner · 1 January 2022Sponsor and participant in the annual Venezuelan Gastroenterology Congress (XLIII edition). Grupo LETI organized scientific symposia (Helicobacter Pylori, Hepatic Immunology) and hosted a dinner for the new SOVEGASTRO board 2022-2024. Products featured include Hepagras, Ulgarín, Rifamix, Zóntricon, and Dobracid.
• MEGATcoreStrategic or Co-development Partner · 1 January 2019MEGAT is the sister company of Grupo LETI in Ecuador, commercializing products from Grupo LETI's portfolio for the Ecuadorian market. This partnership extends Grupo LETI's geographic reach beyond Venezuela, establishing a presence in the Andean region. Operations in Ecuador began in 2019.

Scale indicators19 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Laboratorios Calox International: Venezuelan pharmaceutical manufacturer operating in Caracas with branded generics, OTC, and specialty products. Direct competitor to LETI in the Venezuelan market across similar therapeutic categories (cardiovascular, anti-infective, anti-inflammatory) and distribution channels (pharmacy chains, hospitals).
• Laboratorios Elmor: Venezuelan pharmaceutical company producing branded and generic pharmaceutical products. Direct competitor to LETI within Venezuela with similar therapeutic focus and pharmacy/hospital distribution, though smaller scale and with less proprietary drug delivery technology.
• Laboratorios Stein: Costa Rica-based pharmaceutical manufacturer with branded generics and OTC products distributed across Central America and the Caribbean. Comparable to LETI in mid-sized regional branded generic manufacturer model and emerging market focus, though operates in different geography.
• Laboratorios Alfa: Venezuelan pharmaceutical group with consumer healthcare and pharmaceutical products including branded generics, OTC, and personal care items. Direct competitor to LETI within Venezuela with similar GTM through pharmacy chains and mass-market positioning.

Regional players

• Genfar: Latin American generics-focused pharmaceutical company headquartered in Colombia with operations across Andean and Central American markets. Comparable to LETI's Genven subsidiary as a generics-focused brand with regional reach, and a potential template/competitor for LETI's international expansion plans.

Broad incumbents

• Laboratorios Bagó: Argentina-based multinational pharmaceutical manufacturer with broad branded generics portfolio across Latin America. Directly comparable to LETI as a regional Latin American pharma group with diversified branded/generic portfolio, in-house manufacturing, and multiple country presence—though Bagó is materially larger and more geographically diversified.
• Roemmers: Argentina-headquartered pharmaceutical group with branded specialty and OTC portfolio across Latin America. Comparable to LETI in its mix of branded ethical drugs and OTC products sold through pharmacy chains, with proprietary R&D, though Roemmers has stronger international presence and cardiometabolic focus.
• Eurofarma Laboratórios: Brazilian multinational pharmaceutical company with branded generics, specialty, and OTC portfolio across Latin America. Comparable to LETI in vertically integrated manufacturing, generic+branded model, and focus on accessible medicines, though Eurofarma is significantly larger and more internationalized.
• Teva Pharmaceutical Industries: Global generic pharmaceutical leader with strong Latin American presence. Comparable to LETI/Genven in the broad generic medicines category, and relevant as a benchmark for international generic expansion given Teva's portfolio depth and regional infrastructure.
• Sandoz: Global leader in generic pharmaceuticals and biosimilars, a Novartis division with operations in over 100 countries. Comparable to LETI's Genven generics franchise in product category, and a key competitor/benchmark for any international generic expansion plans due to scale and regulatory expertise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/GrupoLeti
• YouTubeyoutube.com/channel/UCK2yjye_-Hcl4oA9GPybrMg
• Facebookfacebook.com/laboratoriosletisav
• LinkedInlinkedin.com/company/grupoleti
• Instagraminstagram.com/grupoleti

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grupo LETI